



CME DATA SERVICES: DS-27

2026 Market Data Fee Adjustments for Futures and Options

In accordance with your market data agreement, this notice is to inform you of upcoming revisions to CME Group market data fees, effective **January 1, 2026**.

1. Futures and Options Information.

- A. Fees for all CME, CBOT, NYMEX, COMEX and GME futures and options Information will increase by up to 3.5%.
- B. The revised Fees are available in the January 2026 Market Data Fee List located in the fee section of the [Market Data Policy Education Center](#).
- C. Annual CME DataMine subscription Fees will be effective at your CME DataMine subscription renewal in 2026 and can be found in the [CME DataMine product catalog](#).
- D. If you have any questions related to the Fees for CME, CBOT, NYMEX, COMEX and GME Information, please contact your account manager or marketdata@cmegroup.com.

2. Derived Data License Fees.

- A. All annual derived data license Fees will increase by up to 3.5%.
- B. Please contact CMEGroupDerivedData@cmegroup.com if you have any questions.



[Privacy Notice](#) | [Terms of Use](#) | [Cookie Notice](#) | [Disclaimer](#)

rates, equity indexes, FX, energy, agricultural products and metals.

The information in this email has been compiled by CME Group for general purposes only and is not intended to provide, and should not be construed as, advice. Although every attempt has been made to ensure the accuracy of the information within this communication as of the date of publication, CME Group assumes no responsibility for any errors or omissions and will not update it. Additionally, all examples and information in this communication are used for explanation purposes only and should not be considered investment advice or the results of actual market experience. Any information denoting past or historical performance is not indicative of future performance and no reliance shall be placed on such information. CME Group does not represent that any material or information contained in this website is appropriate for use or permitted in any jurisdiction or country where such use or distribution would be contrary to any applicable law or regulation.

Exchange traded derivatives and cleared over-the-counter ("OTC") derivatives are not suitable for all investors and involve the risk of loss. Exchange traded and OTC derivatives are leveraged instruments and because only a percentage of a contract's value is required to trade, it is possible to lose more than the amount of money initially deposited. This email does not (within the meaning of any applicable legislation) constitute a Prospectus or a public offering of securities; nor is it a recommendation to buy, sell or retain any specific investment or service.

In Australia, each of Chicago Mercantile Exchange Inc. (ARBN 103 432 391), The Board of Trade of the City of Chicago Inc (ARBN 110 594 459), the New York Mercantile Exchange Inc (ARBN 113 929 436) and Commodity Exchange, Inc. (ARBN 622 016 193) is a registered foreign company in Australia and holds an Australian market licence.

In Hong Kong, CME Group is authorised by the Hong Kong Securities and Futures Commission (the "SFC") to provide Automated Trading Services ("ATS") via its GLOBEX system, and its CME Clearing System under Part III of the Securities and Futures Ordinance (the "SFO").

In Japan, CME Inc. has a Foreign Clearing Organisation (FCO) license under the Financial Instruments and Exchange Act of Japan.

In Singapore, CME Inc., CBOT, NYMEX and COMEX are regulated as a recognized market operator and CME Inc. is regulated as a recognized clearing house under the Securities and Futures Act (Chapter 289) ("SFA"). Save as aforesaid, none of the CME Group entities are licensed to carry on regulated activities under the SFA or to provide financial advisory services under the Financial Advisers Act (Chapter 110) in Singapore.

None of CME Group entities are registered or licensed to provide, nor does it purport to provide, financial services of any kind in some jurisdictions, including, but not limited to, India, Korea, Malaysia, New Zealand, People's Republic of China, Philippines, Taiwan, Thailand, and Vietnam and in any jurisdiction where CME Group is not authorized to do business or where such distribution would be contrary to the local laws and regulations.

In Japan, this communication is for distribution solely to certain qualified sophisticated investors as defined in the Commodities Futures Act of Japan (Law No. 239 of 1950, as amended) and the related rules, as appropriate; other than that, the information contained in this communication is not directed at any person in Japan.

In the Republic of Korea, this communication is for distribution solely to "professional investors" (as defined in Article 9(5) of the Financial Investment Services and Capital Markets Act and related rules) in response to a request from such professional investors or through a licensed investment broker.

This communication is for distribution in Singapore solely to persons holding a capital markets services licence for trading in futures contracts or exempt from such requirements.

You are advised to exercise caution in relation to the information contained herein. If you are in any doubt about any of the contents of this communication, you should obtain independent professional advice.

This email has not been reviewed or approved by any regulatory authority and access shall be at the liability of the user. Any trades undertaken in the aforesaid jurisdictions will be at the sole risk of the relevant investor and should always be made in compliance with the local laws and regulations applicable in such jurisdictions.

CME Group®, the CME Group Globe logo, and CME® are trademarks of Chicago Mercantile Exchange, Inc.

Copyright © 2025 CME Group. All rights reserved.

Mailing Address: 20 South Wacker Drive, Chicago, Illinois 60606

[Unsubscribe](#)

[Update my subscription settings](#)